Oregon Health and Science University, Portland, Oregon, USA.
J Infect Dis. 2010 Jul 1;202(1):104-8. doi: 10.1086/653122.
The experimental cytomegalovirus UL97 kinase inhibitor maribavir was used to treat 2 cases of infection in which viral mutations that conferred ganciclovir and foscarnet resistance had evolved sequentially. In one case, viral shedding was cleared without evidence of maribavir resistance in an isolate obtained after therapy. In the other case, a high-grade viremia was initially reduced 50-fold but rebounded 2 months later, coincident with the emergence of viral UL97 mutations T409M and H411Y, which confer maribavir resistance. The relatively rapid onset of maribavir resistance probably resulted from incomplete viral suppression in an immunosuppressed host with a high viral load.
实验性巨细胞病毒 UL97 激酶抑制剂马拉韦罗曾用于治疗 2 例先后出现导致更昔洛韦和膦甲酸钠耐药的病毒突变的感染。在 1 例中，治疗后获得的分离物中未检测到马拉韦罗耐药，病毒脱落得到清除。在另 1 例中，最初高病毒血症降低了 50 倍，但 2 个月后又反弹，同时出现了赋予马拉韦罗耐药性的病毒 UL97 突变 T409M 和 H411Y。马拉韦罗耐药的出现相对较快可能是由于病毒载量高的免疫抑制宿主中病毒抑制不完全所致。
